Aug 07, 2017 7:00am EDT Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
Jul 17, 2017 7:00am EDT Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
Jun 15, 2017 7:00am EDT Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017
Jun 08, 2017 7:00am EDT Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis
Jun 01, 2017 7:00am EDT New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017
May 30, 2017 7:00am EDT Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update
May 16, 2017 7:00am EDT Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
May 03, 2017 7:00am EDT Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
Apr 25, 2017 7:00am EDT Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
